Jasper Therapeutics, Inc. (JSPR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Redwood City, CA, United States. The current CEO is Jeetinder Singh Mahal.
JSPR has IPO date of 2020-01-10, 64 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $15.15M.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
